acut
exacerb
aex
idiopath
pulmonari
fibrosi
ipf
wellknown
phenomenon
cours
ipf
critic
impact
natur
cours
prognosi
howev
real
natur
aex
exact
pathobiolog
yet
clear
therefor
incid
diagnost
criteria
treatment
method
clearli
defin
recent
work
group
area
propos
new
consensu
definit
diagnost
criteria
aexipf
base
avail
evid
publish
first
consensu
definit
aeipf
propos
collard
et
al
new
report
uptod
extens
review
perform
pulmonologist
radiologist
pathologist
detail
inform
avail
although
diffus
alveolar
damag
dad
pattern
superimpos
usual
interstiti
pneumonia
uip
recogn
among
pathologist
mani
year
ago
kondoh
et
al
first
report
three
case
aexipf
much
interest
paid
aexipf
martinez
colleagu
found
appar
acut
rapid
progress
lung
diseas
almost
half
patient
die
ipfrel
caus
among
placebo
group
random
clinic
trial
kim
et
al
report
clinic
radiolog
patholog
featur
case
aexipf
among
patient
ipf
sever
studi
report
signific
aexipf
studi
provok
interest
result
first
consensu
definit
diagnost
criteria
propos
expert
committe
sponsor
ipf
clinic
research
network
nation
heart
lung
blood
institut
nhlbi
attempt
standard
futur
research
aexipf
thought
idiopath
acut
worsen
respiratori
condit
patient
ipf
differ
pathobiolog
differ
outcom
worsen
caus
known
caus
exclus
known
caus
infect
requir
invas
procedur
bronchoalveolar
lavag
bal
thought
import
step
diagnosi
aexipf
therefor
committe
defin
aexipf
acut
clinic
signific
deterior
unidentifi
caus
propos
five
diagnost
criteria
includ
presenc
ipf
clinic
worsen
less
day
durat
presenc
new
radiolog
abnorm
highresolut
comput
tomographi
hrct
ie
bilater
groundglass
opacificationconsolid
evid
pulmonari
infect
endotrach
aspir
bal
exclus
altern
etiolog
eg
heart
failur
pulmonari
embol
identifi
caus
acut
lung
injuri
five
requir
satisfi
diagnosi
definit
aexipf
diagnosi
suspect
aexipf
howev
clinic
practic
invas
procedur
feasibl
mani
critic
ill
patient
therefor
import
clarifi
exact
natur
aexipf
diagnosi
treatment
acut
exacerb
aex
idiopath
pulmonari
fibrosi
ipf
import
event
exert
critic
impact
prognosi
patient
ipf
real
natur
etiolog
pathobiolog
therapi
yet
clear
previous
defin
idiopath
acut
worsen
respiratori
condit
patient
ipf
recent
intern
work
group
propos
new
definit
remov
idiopath
thu
exclud
necess
invas
procedur
diagnosi
hope
new
definit
diagnost
criteria
improv
feasibl
futur
research
find
effect
treatment
key
question
real
naturepathobiolog
aexipf
acceler
origin
diseas
process
clinic
occult
unrecogn
secondari
condit
infect
aspir
acut
exacerb
idiopath
pulmonari
fibrosi
unrecogn
condit
similar
clinic
featur
infect
aexipf
also
potenti
increas
suscept
infect
patient
secondari
therapi
underli
diseas
difficult
exclud
possibl
infect
time
diagnosi
aexipf
may
unrecogn
viral
infect
furthermor
epidemiolog
studi
show
aexipf
frequent
patient
take
immunosuppress
drug
winter
spring
season
respiratori
viral
infect
common
confirm
hypothesi
wooten
et
al
studi
presenc
viru
prospect
collect
bal
fluid
aexipf
patient
use
multiplex
polymeras
chain
reaction
panvir
microarray
highthroughput
cdna
sequenc
found
respiratori
virus
six
patient
two
rhinovirus
one
parainfluenza
coronaviru
herp
simplex
epsteinbarr
viru
torqu
teno
viru
patient
signific
torqu
teno
viru
certain
detect
similar
percentag
sampl
acut
lung
injuri
control
group
later
bando
et
al
report
seem
unlik
torqu
teno
viru
would
directli
involv
onset
aexipf
could
reflect
immunosuppress
state
host
treatment
sever
studi
also
confirm
low
preval
infect
organ
aexipf
result
suggest
major
aexipf
infect
although
still
possibl
viral
trigger
acut
lung
injuri
disappear
time
clinic
present
aspir
gastric
content
caus
acut
lung
injuri
manifest
dad
lung
biopsi
occult
aspir
gastric
content
propos
one
possibl
caus
aexipf
joyc
lee
et
al
measur
bal
pepsin
level
patient
aexipf
stabl
ipf
control
show
measur
bal
pepsin
patient
stabl
ipf
suggest
occult
aspir
common
ipf
eight
aexipf
patient
high
bal
pepsin
level
suggest
occult
aspir
may
play
role
case
anoth
studi
show
significantli
higher
rate
gastroesophag
reflux
acut
exacerb
patient
asymmetr
ipf
exacerb
occur
affect
side
right
lung
depend
side
sleep
post
hoc
analysi
placebo
arm
three
clinic
trial
show
aexipf
occur
subject
antacid
therapi
proton
pump
inhibitor
blocker
presum
antacid
therapi
reduc
potenti
microaspirationrel
lung
injuri
furthermor
among
patient
assign
placebo
group
three
trial
patient
take
antacid
treatment
baselin
smaller
decreas
forc
vital
capac
fvc
week
suggest
antacid
treatment
could
benefici
patient
ipf
abnorm
acid
gastroesophag
reflux
seem
contribut
diseas
progress
howev
recent
post
hoc
analys
inpulsi
clinic
trial
show
incid
aexipf
among
placebo
group
take
antacid
baselin
high
compar
group
fvc
declin
greater
degre
compar
patient
receiv
antacid
medic
baselin
suggest
patient
treat
antacid
baselin
may
actual
wors
reason
contradictori
result
certain
may
due
persist
acid
gastroesophag
reflux
antacid
therapi
nonacid
compon
present
reflux
result
suggest
although
patient
aspir
may
trigger
aexipf
major
aexipf
case
caus
aspir
role
gastroesophag
reflux
aexipf
ipf
certain
prospect
studi
verifi
efficaci
antacid
warrant
therefor
reason
think
acut
exacerb
ipf
clinic
unrecogn
secondari
condit
although
condit
may
act
trigger
factor
next
possibl
aexipf
may
acceler
underli
diseas
process
enhanc
fibroprolifer
although
research
ongo
molecular
mechan
underli
aexipf
remain
poorli
understood
activ
immun
system
disord
coagulationfibrinolysi
oxid
stress
may
contribut
pathophysiolog
aexipf
aexipf
similar
acut
respiratori
distress
syndrom
ard
clinic
radiolog
patholog
pathobiolog
may
also
similar
investig
possibl
collard
et
al
compar
biomark
profil
stabl
ipf
aexipf
ard
ard
level
receptor
advanc
glycat
endproduct
rage
marker
type
alveolar
epitheli
cell
aec
injuryprolifer
proinflammatori
cytokin
marker
endotheli
dysfunct
activ
coagul
inhibit
fibrinolysi
elev
wherea
aexipf
group
lower
level
rage
higher
level
kreb
von
surfact
proteind
marker
type
ii
aec
prolifer
andor
injuri
similar
stabl
ipf
greater
degre
absenc
type
cell
injuri
signatur
combin
exuber
elev
type
ii
cell
marker
provid
support
hypothesi
aexipf
predominantli
manifest
acceler
underli
diseas
process
rather
result
second
differ
kind
injuri
hypothesi
also
support
gene
express
studi
konishi
et
al
found
global
gene
express
pattern
aexipf
almost
ident
stabl
ipf
aexipf
exhibit
fibrosi
signatur
ident
stabl
ipf
dramat
shift
indic
new
process
dramat
shift
cellular
phenotyp
gene
relat
stress
respons
significantli
differenti
express
indic
infecti
etiolog
overwhelm
inflammatori
respons
result
suggest
basic
patholog
process
aexipf
similar
stabl
ipf
enhanc
degre
trigger
acut
acceler
ipf
diseas
process
discuss
previous
infect
aspir
trigger
factor
although
main
pathobiolog
process
aexipf
infect
aspir
gastric
content
surgeri
procedur
mani
report
develop
aexipf
surgeri
lung
resect
also
extrathorac
even
surgic
lung
biopsi
bal
mechan
certain
surgic
procedur
mechan
stress
high
tidal
volum
high
oxygen
flow
intraop
fluid
imbal
may
trigger
aexipf
relationship
ambient
air
pollut
exacerb
respiratori
diseas
asthma
chronic
obstruct
pulmonari
diseas
well
establish
aexipf
may
caus
air
pollut
johansen
et
al
studi
relationship
develop
aexipf
exposur
air
pollut
use
data
collect
fix
telemonitor
system
situat
throughout
korea
sinc
patient
ipf
found
signific
relationship
aexipf
exposur
ozon
day
prior
aeipf
pollut
suggest
increas
exposur
ozon
contribut
develop
aex
patient
mani
biolog
etanercept
infliximab
nonbiolog
ambrisentan
agent
immunomodulatori
agent
interferon
everolimu
leflunomid
antineoplast
therapi
provok
interstiti
pneumonia
may
mimic
aex
patient
preexist
ipf
minegishi
colleagu
report
incid
acut
respiratori
deterior
relat
anticanc
treatment
among
patient
lung
cancer
accompani
idiopath
interstiti
pneumonia
therefor
seem
aexipf
may
acut
acceler
underli
fibroprolif
process
trigger
extrins
unknown
insult
patient
ipf
alreadi
predisposit
exagger
fibrosi
secondari
abnorm
wound
heal
sever
studi
report
increas
incid
aexipf
andor
higher
mortal
patient
ipf
lung
cancer
surgeri
major
thorac
surgeri
compar
patient
without
ipf
suggest
increas
suscept
ipf
patient
extrins
insult
voltolini
et
al
report
patient
interstiti
lung
diseas
ild
mostli
ipf
higher
incid
postop
ard
presum
aexipf
compar
patient
without
ild
vs
p
studi
show
aexipf
common
patient
advanc
diseas
low
fvc
low
diffus
capac
carbon
monoxid
low
walk
distanc
pulmonari
hypertens
poor
baselin
oxygen
increas
dyspnea
score
recent
declin
fvc
younger
age
comorbid
coronari
arteri
diseas
higher
bodi
mass
index
histori
aex
elev
serum
level
baselin
report
associ
increas
risk
aexipf
addit
serum
neutrophil
elastas
lactat
dehydrogenas
level
suggest
marker
aexipf
sever
new
possibl
biomark
level
circul
fibrocyt
highmobl
group
monocyt
chemotact
solubl
protein
marker
oxid
stress
heat
shock
protein
heat
shock
protein
mediat
fibrosi
induc
intercellular
adhes
report
elev
peripher
blood
patient
aexipf
tachibana
et
al
demonstr
patient
aexipf
increas
serum
inhibitor
transform
growth
product
fibroblast
signal
associ
better
prognosi
aexipf
consensu
opinion
intern
work
group
definit
includ
acut
respiratori
event
character
new
bilater
groundglass
opacificationconsolid
fulli
explain
cardiac
failur
fluid
overload
littl
clinic
biolog
support
distinguish
idiopath
nonidiopath
respiratori
event
howev
cardiogen
pulmonari
edema
believ
distinct
pathobiolog
favor
prognosi
compar
caus
acut
respiratori
deterior
bilater
radiolog
involv
parallel
berlin
criteria
ard
exclud
isol
congest
heart
failur
therefor
revis
definit
aex
ipf
acut
clinic
signific
respiratori
deterior
character
evid
new
widespread
alveolar
abnorm
patient
ipf
inclus
result
diagnost
criteria
feasibl
clinician
clinic
trialist
difficulti
requir
invas
microbiolog
evalu
criteria
two
chang
previou
consensu
diagnost
criteria
remov
idiopath
diagnost
criteria
acut
exacerb
chang
definit
aexipf
exclus
infect
potenti
trigger
longer
requir
howev
committe
state
chang
discount
clinic
relev
identifi
infect
present
treatment
may
import
overal
manag
patient
addit
suggest
futur
studi
need
test
whether
aggress
investig
eg
bal
bronchoscop
cryobiopsi
surgic
lung
biopsi
patient
aexipf
improv
outcom
chang
time
interv
day
typic
less
month
major
opinion
time
period
arbitrari
made
flexibl
allow
case
fall
outsid
time
window
day
week
phrase
typic
less
month
seem
retain
precis
allow
inclus
except
physician
feel
clinic
repres
acut
exacerb
flexibl
time
interv
may
lead
heterogen
among
clinic
trial
endpoint
definit
aex
could
complic
comparison
trial
new
consensu
report
emphas
import
hrct
diagnosi
aexipf
state
hrct
chest
obtain
patient
safe
perform
transbronchi
biopsi
limit
util
surgic
lung
biopsi
gener
avoid
high
morbid
nonelect
set
although
new
consensu
criteria
exclud
workup
infect
diagnosi
still
import
exclud
possibl
presenc
activ
infect
trigger
factor
treatment
differ
consid
corticosteroid
still
wide
use
aexipf
also
one
therapeut
candid
futur
clinic
trial
misdiagnosi
infect
aexipf
big
mistak
furthermor
clinic
radiolog
featur
infect
especi
viral
infect
similar
aexipf
actual
song
et
al
report
almost
half
patient
acut
respiratori
deterior
among
ipf
infect
recent
moua
et
al
also
report
high
frequenc
infect
among
patient
admit
acut
respiratori
worsen
manag
support
care
remain
mainstay
treatment
aexipf
focus
palliat
symptom
correct
hypoxemia
supplement
oxygen
high
inhospit
mortal
patient
respiratori
failur
intern
guidelin
manag
ipf
made
weak
recommend
use
mechan
ventil
patient
although
valueladen
decis
best
made
patient
clinician
famili
ahead
time
base
firm
understand
patient
goal
care
guidelin
also
give
weak
recommend
corticosteroid
major
patient
aexipf
base
high
valu
anecdot
report
benefit
high
mortal
associ
aexipf
data
suggest
respons
highdos
corticosteroid
treatment
may
depend
type
hrct
lesion
better
respons
achiev
peripher
pattern
organ
pneumonia
pattern
patholog
compar
dad
pattern
difficulti
exclus
infect
especi
earli
phase
broadspectrum
antibiot
commonli
use
kubo
et
al
report
better
surviv
anticoagul
group
mostli
due
reduc
mortal
associ
aexipf
suggest
efficaci
anticoagul
treatment
aexipf
howev
small
sampl
size
methodolog
limit
studi
benefit
anticoagul
therapi
controversi
recent
clinic
trial
anticoagul
patient
ipf
show
actual
increas
mortal
warfarintr
group
sever
innov
treatment
aexipf
mostli
tri
japan
includ
polymyxin
bimmobil
fiber
column
pmx
hemoperfus
tacrolimu
intraven
thrombomodulin
rituximab
combin
plasma
exchang
intraven
immunoglobulin
usual
administ
addit
corticosteroid
howev
studi
mostli
small
uncontrol
use
histor
data
parallel
untreat
control
arm
aexipf
certainli
lead
caus
hospit
death
among
patient
ipf
death
ipf
preced
aex
clinic
trial
sever
investig
treatment
ipf
suggest
chronic
treatment
ipf
might
reduc
incid
aexipf
trial
sildenafil
inhibitor
show
numer
reduct
aexipf
patient
given
sildenafil
versu
placebo
vs
number
event
small
differ
statist
signific
phase
ii
studi
pirfenidon
japanes
patient
ipf
termin
earli
base
higher
frequenc
aexipf
placebo
group
pirfenidon
group
howev
phase
iii
trial
japan
signific
differ
observ
definit
phase
iii
clinic
trial
pirfenidon
report
acut
exacerb
endpoint
pirfenidon
suggest
reduc
risk
aex
postop
data
observ
therefor
high
risk
confound
three
placebocontrol
clinic
trial
nintedanib
includ
aex
key
secondari
endpoint
phase
ii
trial
nintedanib
time
first
investigatorreport
aex
delay
nintedanib
group
howev
phase
iii
trial
one
trial
demonstr
signific
reduct
risk
acut
exacerb
nintedanib
trial
show
signific
differ
pool
data
demonstr
reduct
risk
adjud
confirm
suspect
aex
nintedanib
therapi
placebo
vs
nintedanib
p
pool
data
metaanalys
data
phase
ii
tomorrow
trial
two
phase
iii
inpulsi
trial
includ
patient
nintedanib
n
placebo
n
show
hazard
ratio
time
first
aex
ci
p
favor
nintedanib
trial
drug
acetylcystein
monotherapi
bosentan
sildenafil
show
impact
prevent
aexipf
ambrisentan
imatinib
tripl
therapi
combin
prednison
azathioprin
acetylcystein
warfarin
actual
increas
risk
ipf
conclus
aexipf
import
event
exert
critic
impact
prognosi
patient
ipf
real
natur
etiolog
pathobiolog
therapi
yet
clear
mani
studi
perform
consensu
report
suggest
aexipf
may
acut
acceler
underli
fibroprolif
process
trigger
variou
extrins
unknown
insult
patient
ipf
alreadi
predisposit
exagger
fibrosi
due
abnorm
wound
heal
previous
defin
idiopath
acut
worsen
respiratori
condit
patient
ipf
recent
intern
work
group
propos
new
definit
remov
idiopath
thu
exclud
necess
invas
procedur
diagnosi
littl
clinic
biolog
support
distinguish
idiopath
nonidiopath
respiratori
event
hope
new
definit
diagnost
criteria
improv
feasibl
futur
research
find
effect
treatment
